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Intrauterine transfusion (IUT) therapy is the treatment of choice in severe hemolytic disease of the fetus. This treat ment automatically implies the introduction of alloantigens in the fetal circulation, which might potentially influence the unprimed fetal immune system. The present study provides evidence that the fetal immune system is indeed prone to modulations of the T-cell receptor BV (TCRBV) repertoire as a result of IUT treatment. Most notably, IUT therapy affects the composition of the CD4+ repertoire, whereas this effect may be obscured in the CD8* subset. The CD8+ subset was found to be influenced by alterations of the TCRBV reper toire both in IUT patients and controls, suggesting that mod ulations in this subset could be the result of developmental influences. A more detailed analysis on the composition of the individual TCRBV families was performed by evaluating the distribution of the complementarity determining region 3 (CDR3) size lengths of [32P]-radiolabeled TCRBV tran scripts. Using this technique, referred to as spectratyping, only marginal changes were observed in the CD4+ and CD8+ subset during the course of treatm ent and gestational devel opment of both lUT-treated patients and controls. Therefore, the alterations in the overall TCRBV repertoire were of a quantitative rather than a qualitative nature. To evaluate whether the observed alterations in TCRBV usage-frequencies were a reflection of an allo-reactive response, a primed lymphocyte test (PLT) was performed in 3 lUT-treated pa tients. We observed th at IUT, performed as early as 23 weeks of gestation, may induce the establishment of memory T cells against the IUT donor. However, there was no associa tion between the observed changes in TCRBV repertoire and the magnitude of the secondary allo-reactive response. Under physiological circumstances, the development of the fetal immune system occurs in an almost sterile and alloantigen-free environment. Throughout gestation, the fetus is mainly confronted with both self and also selected maternal antigens. Therefore, it would not be unreasonable to assume that the introduction of allo-antigens into the fetal circulation by intrauterine transfusion (IUT) might have an impact on the fetal immune system. However, the immunologic conse quences of IUT treatment have, until now, not been investi gated in great detail.
Blood transfusions are known to have potent immunomod ulatory properties. For instance, administration of an HLA-(B),DR-matched blood transfusion before transplantation can result in an increased allograft survival.4"' This toleration effect might be the result of induction of anergy, suppression, that these transfusions result in cytotoxic T-lymphocyte non responsiveness to donor antigens1 1 and can result in the ab sence of several T-cell receptor BV (TCRBV) families. Because tolerance is easier to induce in neonates than in 10 adults, 11 .12 the effect of allogeneic blood transfusion might be even more pronounced in the fetus.
IUT treatment offers a unique model to simultaneously investigate the effect of blood transfusion on the fetal im mune repertoire and the allogeneic response of an unprimed immune system in vivo. Direct access to the umbilical cord under ultrasound guidance has made it possible to obtain peripheral blood of the fetus at different time points in gesta tion.2 '3 To evaluate semiquantitative influences of IUT therapy on the fetal CD4+ and CD8+ TCRBV repertoire, the polymerase chain reaction (PCR) technique with 25 TCRBV familyspecific oligonucleotide primers was used to determine the TCRBV gene element usage both before and after IUT treat ment in 5 fetuses. Changes in the distribution of complemen tary determining region 3 (CDR3) length of the TCRs during the course of therapy were analyzed using spectratyping.11 The results were compared with 5 patients who underwent fetal blood sampling (FBS) but did not receive IUT therapy. In 3 IUT-treated patients, the magnitude of the alloresponse against several IUT donors was determined by a primed lymphocyte test (PLT) in cord blood (CB), obtained ;
MATERIALS AND METHODS

IUT Patients
The use of patient material (IUT-treated patients and controls) for research purposes was approved by the Commission of Medical Ethics of the University Hospital Leiden (protocol P244/94).
Patient and transfusion characteristics are shown in Table 1 . Four fetuses (patients no. 1 through 4) received IUT therapy with unre lated donor erythrocytes for treatment of severe hemolytic disease caused by Rhesus(D) antibodies. The other fetus (patient no. 5) received maternal platelets for management of fetal allo-immune thrombocytopenia, which was induced by maternal antibodies di rected against a paternal private antigen. The mother of this fetus 
Controls
Fetal blood was obtained from 5 fetuses of other patients (patients no. 6 through 10) for prenatal diagnosis (Table 1) . In 2 patients, FBS was performed to determine the possible cause of growth retar dation in utero (patients no. 6 and 8). Patient no. 6 was born at 40 weeks and had a weight of 2,675 g. This neonate left the hospital in good health shortly after birth. The other infant (patient no. 8) was born at 35 weeks of gestation, had a weight of 890 g, and showed signs of dysmaturity. This child left the hospital in good condition 12 weeks after delivery. Patient no. 10 underwent an FBS procedure to confirm an XO mosaicism that was observed after amniocentesis. However, this diagnosis could not be confirmed in fetal blood, in cord blood at delivery, or in placental tissue. This infant left the hospital in good condition directly after birth. Ultra sound imaging showed multiple congenital heart defects in patient no. 7 and corrective heart surgery was successfully performed 3 weeks after birth. Patients no. 7 and 8 received two blood transfu sions after birth for correction o f anemia induced by laboratory testing. Patient no. 9 had a Dandy Walker malformation and died shortly after birth due to severe neurological impairment. FBS in control patients failed to show chromosomal aberrations or any other abnormalities that could explain the respective medical conditions. The FBS procedure in the control patients was performed without administration of premedication to the mothers. Furthermore, these fetuses did not receive medication to prevent fetal movement. lected in citrate-phosphate-dextrose solution. Erythrocytes were fil tered after buffycoat removal and contained less than 2 x 10ft leukocytes per unit. The hematocrit was adjusted to approximately 0.85 L/L by using 0.9% saline. Donor blood was irradiated with 25 Gy and administered within 3 hours after preparation.
Intrauterine platelet transfusions. Maternal platelets were col lected using a cell separator (COBE, Lakewood, CA). After centrifu gation, maternal plasma was removed and platelets (containing an average of 50 X 106 leukocytes) were resuspended in 50-mL citratephosphate-dextrose plasma from a male, blood group AB donor. Maternal platelets were irradiated with 25 Gy and administered within 2 hours after preparation, 
Collection of the Samples
Preparation of IUT
RESULTS
Spectratyping
Spectratyping o f the different TCRBV families was determined according to the methodology described by Gorski et al.1-1 1 /j.L o f cDNA was used lor each PCR. PCR conditions were compaTo determine whether IUT therapy had any influence on the TCRB repertoire, we compared the composition of the TCRBV repertoire, both before and after IUT treatment, in 5 IUT patients using a semiquantitative PCR and spectratyp ing. To exclude developmental influences, similar experirable to those described above, with the exception that 20 pmol of nients were performed in 5 control patients. In all patients. 
PLT
The proliferative alloresponses of 3 IUT-treated patients were determined against 8 original IUT donors using PLT. Briefly, 5 X 10'1 responder cells were cultured with 5 X lO4 irradiated stimulators (30 Gy) in 96-well round-bottomed microtiter plates (Costar, Cam bridge, MA). Cultures were incubated for 3 days at 37°C in humidi fied air containing 5% C 0 2. Cells were subsequently pulsed overthe first FBS was used as a reference. In IUT-treated patients, the first FBS was performed before the onset of transfusion therapy to determine the fetal hematocrit or platelet count. On average, the first FBS was performed at 26.6 weeks in the IUT group compared with 27.4 weeks in the control group (Table 1 ). The composition of the TCRBV repertoire of this CB sample was compared with a sample obtained at a second time point. For 3 IUT patients (nos. 1, 2, and 5) , we compared the first FBS with a CB sample before the last IUT. This was performed to exclude possible contamination with donor leukocytes, because the interval between the last IUT and delivery was less than 2 weeks. The second time point of measurement was at 35 weeks of gestation, on aver age in the IUT group, compared with 38.8 weeks in control group (Table 1) . The median interval between two measurements was 7 weeks for the IUT group and 10 weeks for the control group.
Semiqua.ntitati.ve Analysis of the TCRBV Gene Usage Frequencies Using PCR
The TCRBV repertoires of CD4* and C D 8' T-cell subsets were analyzed separately because they display different us-age profiles.14,17,1,1 The individual TCRBV repertoires in IUTtreated patients and controls are shown in Fig 1A and B. Each individual patient showed a distinct usage pattern of semiquantitative PCR analysis (Fig 1A and B) , in the CD4 subset did not result in alterations of the respective spectratypes. One exception was patient no. 4, in whom major changes in the distribution of the CDR3 lengths were noted during the course of IUT treatment. Before IUT treatment, this patient showed a very restricted TCRB V repertoire that differed from all other patients in that they showed a more or less binomial distribution of all TCRBV products. These
These results show that, in general, the observed expansions or contractions of TCRBV gene usage, as determined by the various TCRBV gene elements in the C D 4+ and CD8+ subsets. All TCRBV gene elements were used for each indi vidual patient both in IUT-treated patients and controls, ex cept for patient no. 4 (Fig 1A) . In this patient, several TCRBV gene segments remained undetectable in the CD4+ subset at 32 weeks of gestation (TCRBV 17 and 19 through 24). However, most of these genes were detected in cord blood after delivery, although the usage frequencies of results were comparable with the semiquantitative PCR, TCRBV 20 through 22 remained low in this patient.
To determine changes in the overall CD4' and C D 81 ' TCRBV repertoire, correlation coefficient calculations (R2) of the first FBS and a sample at a second time point of analysis were determined ( Table 1 ). The results showed that, in 4 of 5 IUT-treated patients, significant changes occurred in the TCRBV repertoire of the CD4+ subset (mean R2 = ,301). In 1 patient with hemolytic disease, the overall CD4+ TCRBV repertoire was relatively unaffected after IUT ther apy (/?* = .851) and was therefore comparable to the control patients. In the control group, the CD4+ subset remained fairly stable during fetal development (mean R2 = .899). Close examination of our results also showed differences in TCRBV usage patterns of IUT patients before the onset of transfusion therapy when compared with controls. Although these differences were observed in several TCRBV families, the statistical significance disappeared after multiparameter analysis. This was due to loss of statistical power in this limited group of patients (data not shown). However, the gene usage of TCRBV 19 in the C D 8+ subset of the first FBS was significantly increased (uncorrected P value = .0013, corrected P value = .032) in all of the IUT-treated patients
Proliferative Responses to the Original IUT Donors
Finally, we determined if these molecular changes in the CD4 subset of IUT-treated patients were a reflection of an allo-reactive response against the IUT donor. Of 3 IUTtreated patients (patients no. 1, 2, and 3), sufficient numbers o f CB mononuclear cells were available to perform such extended studies. Because no pretransfusion samples of these fetuses were available, proliferative responses against the IUT donors were compared with the responses of healthy nontransfused adult donors that were HLA-DR-matched with the IUT-treated patients (Fig 3) . retai immune system is prone to modulations of the T-cell compartment. This conclusion is derived from the observation that 4 of 5 IUT patients showed changes of the TCRBV gene usage frequencies in the CD4+ subset during the course of therapy. In 1 IUT patient, this subset remained quite stable and was therefore comparable to controls. The control patients showed a fairly stable overall composition of the CD44" sub- 
